Despite treatment with statins, patients with elevated low-density lipoprotein cholesterol
(LDL-C) and triglycerides remain at increased risk for adverse cardiovascular events …

Statins, in addition to healthy lifestyle interventions, are the cornerstone of lipid-lowering
therapy. Other low-density lipoprotein (LDL)-lowering drugs include ezetimibe, bile acid …

Despite steady improvements in cardiovascular disease (CVD) prevention, a scarce
proportion of patients achieve the recommended LDL-C goals, even under high-intensity …

Therapeutic inertia - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI
Homepage MyNCBI Homepage Main Content Main Navigation Preview improvements coming …

Aim: To summarize the evidence in terms of efficacy and safety of head-to-head studies of
high-intensity statins regardless of the underlying population. Materials & methods: A …

Objective The aim was to project the health and economic outcomes of cardiovascular
disease (CVD) among people with type 2 diabetes from Australian public healthcare and …

Introduction: European guidelines recommend the implementation of lipid-lowering
therapies (LLTs) in adults (≥ 65 years) with established atherosclerotic cardiovascular …

Abstract Introduction The 2018 American Heart Association (AHA)/American College of
Cardiology (ACC)/Multisociety blood cholesterol guidelines recommend clinicians consider …

Objectives Attainment of low-density lipoprotein cholesterol (LDL-C) therapeutic goals in
statin-treated patients remains suboptimal. We quantified the health economic impact of …

The aim of this retrospective study was to provide real-world data on lipid-lowering therapy
(LLT) implementation and low-density lipoprotein cholesterol (LDL-C) target achievement in …